Latest revenue
$749.0K
as of 2025-09-30
Latest net income
$-61.1M
as of 2025-09-30
Net margin
-8154.1%
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ATAI is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for ATAI.
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Founded in 2018, atai emerged from the urgent need for better mental health solutions for patients who are under-served by current treatment options. We are advancing a pipeline of product candidates designed to address the complex nature of mental health disorders. We believe that these investigational compounds have the potential to become rapid-acting, durable, and commercially scalable therapies for mental health patients in need of new treatment options. Mental health disorders are highly prevalent and estimated to…
AI summary unavailable — showing raw filing excerpt
Generated from ATAI's filing dated 2025-03-17
Key risks
Item lA. Risk Factors Our business involves significant risks, some of which are described below. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Form 10-K. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price of our common shares could decline, and you could lose part or all of your investment. Please also refer to the section titled “Cautionary Note Regarding Forward-Looking…
AI summary unavailable — showing raw filing excerpt
Generated from ATAI's filing dated 2025-03-17
Profitability
Operating margin
-33341.2%
16.6%Net margin
-48464.0%
278.3%Return on equity
-128.4%
675.3%Return on assets
-93.7%
583.3%Leverage
Debt / equity
0.37×
78.2%Long-term debt / equity
0.12×
96.2%Debt / assets
27.0%
57.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q3 2025 2025-09-30 | $749.0K | +1772.5% | $-61.1M | -132.3% | -8154.1% |
Q2 2025 2025-06-30 | $719.0K | +163.4% | $-27.7M | +51.6% | -3856.6% |
Q1 2025 2025-03-31 | $1.6M | — | $-26.4M | +1.1% | -1699.7% |
Q4 2024 2024-12-31 | $-5.0K | — | $-39.0M | — | — |
Q3 2024 2024-09-30 | $40.0K | -54.0% | $-26.3M | -19.9% | -65715.0% |
Q2 2024 2024-06-30 | $273.0K | +58.7% | $-57.3M | -73.5% | -20993.4% |
Q1 2024 2024-03-31 | $0 | — | $-26.7M | — | — |
Q3 2023 2023-09-30 | $87.0K | — | $-21.9M | — | -25209.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ATAI — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$19.0M
Insider selling
$0
Net activity
+$19.0M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2025-08-14 | Apeiron Investment Group Ltd. / Christian Angermayer 10%+ owner | Purchase | 8,675,799 | $2.19 | $19.0M |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATAI
Institutional value
$137.6M
Total shares held
38.9M
Distinct holders
103
-36 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 11.8M | $41.6M | — | New |
| 2 | UBS Group AG | 7.4M | $26.3M | — | New |
| 3 | BlackRock, Inc. | 6.8M | $24.2M | +4.0M (+143.0%) | Added |
| 4 | Candriam S.C.A. | 3.1M | $10.9M | — | New |
| 5 | VANGUARD FIDUCIARY TRUST CO | 1.3M | $4.4M | — | New |
| 6 | OP Asset Management Ltd | 847.3K | $3.2M | — | New |
| 7 | Brown University | 718.5K | $2.5M | +0 (+0.0%) | No change |
| 8 | CenterBook Partners LP | 707.4K | $2.5M | -73.1K (-9.4%) | Trimmed |
| 9 | AdvisorShares Investments LLC | 567.6K | $2.0M | +19.0K (+3.5%) | Added |
| 10 | Sumitomo Mitsui Trust Group, Inc. | 567.6K | $2.0M | — | New |
| 11 | Nikko Asset Management Americas, Inc. | 567.6K | $2.0M | +106.1K (+23.0%) | Added |
| 12 | Swiss National Bank | 325.9K | $1.2M | +0 (+0.0%) | No change |
| 13 | STABLEFORD CAPITAL II LLC | 286.3K | $1.0M | -5.3K (-1.8%) | Trimmed |
| 14 | Jefferies Financial Group Inc. | 275.9K | $976.7K | — | New |
| 15 | Brummer Multi-Strategy AB | 275.4K | $974.9K | +40.5K (+17.2%) | Added |
| 16 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 266.0K | $941.6K | +76.5K (+40.4%) | Added |
| 17 | Hudson Bay Capital Management LP | 188.5K | $667.2K | — | New |
| 18 | IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 188.0K | $665.6K | +66.6K (+54.9%) | Added |
| 19 | JPMORGAN CHASE & CO | 192.5K | $654.5K | -104.5K (-35.2%) | Trimmed |
| 20 | BIT Capital GmbH | 182.6K | $646.3K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATAI's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.